PUBLICATIONS AND PATENTS

Publications

The InProTher approach is based upon the research from the founder and CSO Peter Holst and the CTO Anne-Marie Andersson. Key in the anti-cancer approach is the Virus-Like-Vaccine technology delivered by hAd19a/64 vaccine vectors, whereas licenses for the MHC class II associated invariant chain technology within HIV and HPV vaccines are the cornerstones in the infectious program.

Cancer Associated Endogenous Retroviruses: Ideal Immune Targets for Adenovirus-Based Immunotherapy. / Bermejo, AV; Ragonnaud, E; Daradoumis J; Holst, PJ. Int. J. Mol. Sci. 2020, 21(14), 4843

Adenovirus based virus-like-vaccines targeting endogenous retroviruses can eliminate growing colorectal cancers in mice. /Neukirch, L.; Nielsen, T. K.; Laursen, H.; Daradoumis, J.; Thirion, C.; Holst, P. J.
Oncotarget, 02, 2019, Vol. 10, 1458-1472.

Replication deficient human adenovirus vector serotype 19a/64: Immunogenicity in mice and female cynomolgus macaques. / Ragonnaud, E.; Schroedel, S.; Mariya, S.; Iskandriati, D.; Pamungkas, J.; Fougeroux, C.; Daradoumis, J.; Thomsen, A. R.; Neukirch, L.; Ruzsics, Z.; Salomon, M.; Thirion, C.; Holst P. J.
Vaccine, 10, 2018, Vol. 36(41), 6212–6222.

Virus-Like-Vaccines against HIV. /Andersson A. M. C.; Schwerdtfeger, M.; Holst, P. J. Vaccines, 01, 2018, Vol. 6(1), 10.

Mucosal Vaccination with Heterologous Viral Vectored Vaccine Targeting Subdominant SIV Accessory Antigens Strongly Inhibits Early Viral Replication. /

Xu, H.; Andersson, A. M.; Ragonnaud, E.; Boilesen, D.; Tolver, A.; Jensen, B. A. H.; Blanchard, J. L.; Nicosia, A.; Folgori, A.; Colloca, S.; Cortese, R.; Thomsen, A. R.; Christensen, J. P.; Veazey, R. S.; Holst, P. J.

EBioMedicine, 04, 2017, Vol. 18, 204-215.

Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen. /

Andersson, A.M. C.; Resende, M.; Salanti, A.; Nielsen, M. A.; Holst, P. J.

Vaccine, 02, 2017, Vol. 35(8), 1140–1147.

Therapeutic Vaccine Against Primate Papillomavirus Infections of the Cervix. /

Ragonnaud, E.; Andersson, A. M. C.; Mariya, S.; Pedersen, A. G.; Burk, R. D.; Folgori, A.; Colloca, S.; Cortese, R.; Nicosia, A.; Pamungkas, J.; Iskandriati, D.; Holst, P. J.

Journal of Immunotherapy, 02, 2017, Vol. 40(2), 51-61.

Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice. /

Andersson, A. M. C.; Holst, P. J.

Journal of Translational Medicine, 12, 2016, Vol. 14(1), 343.

Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations. /

Xu, H.; Andersson, A. M. C.; Ragonnaud, E.; Seaton, K. E.; Sawant, S.; Folgori, A., Colloca, S.; Labranche, S.; Montefiori, D. C.; Tomaras, G. D.; Holst, P. J.

Vaccine, 10, 2016, Vol. 34(44), 5344-5351.

Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility. /

Clausen, T. M.; Pereira, M. A.; Nakouzi, N. A.; Oo, H. Z.; Agerbæk, M. Ø.; Lee, S.; Ørum-Madsen, M. S.; Kristensen, A. R.; El-Naggerm A.; Grandgenett, P. M.; Grem, J. L.; Hollingsworth, M. A.; Holst, P. J.; Theander, T.; Sorensen, P. H.; Daugaard, M.; Salanti, A.
Molecular Cancer Research, 09, 2016, Vol. 14(12), 1288-1299.

Patents

1: A vaccine for use in the prophylaxis and/or treatment of a disease (WO2019043127)

2: A nucleotide vaccine (WO2007062656A3)

3: Priming of an immune response (WO2010057501)